Canadian Cancer Trials Group

This study tests whether adding targeted radiation or surgery to all visible cancer spots, alongside standard hormone therapy, can better control prostate cancer that has spread to a few places (up to 5). About 409 men with hormone-sensitive prostate cancer that has not spread wi…

This study tests new combinations of drugs for people with aggressive B-cell lymphoma that has returned or not responded to treatment. About 129 participants will receive either a new drug combo or standard therapy to see which works better at shrinking tumors. The goal is to fin…

This study tests a new treatment called 177Lu PSMA-617, which delivers radiation directly to prostate cancer cells, against standard chemotherapy (docetaxel) in 200 men with advanced prostate cancer that has spread and is no longer controlled by hormone therapy. The goal is to se…

This study tests new drug combinations given before surgery for non-small cell lung cancer. The goal is to see which treatments shrink tumors most effectively, helping doctors choose the best options for future patients. About 4 people with early-stage lung cancer that can be rem…

This study tests two drugs, CFI-400945 and durvalumab, in 15 women with advanced triple negative breast cancer that cannot be cured. The goal is to see if the combination can shrink tumors or stop them from growing. Participants must have no other treatment options available.

This study tests an experimental drug called CFI-400945 in people with advanced or metastatic breast cancer that has not responded to standard chemotherapy. The goal is to see if the drug can shrink tumors or slow the disease. About 51 participants will receive the drug, and rese…

This study tests a treatment made from two viruses designed to find and kill cancer cells that have a specific marker called MAGE-A3. The viruses also help the immune system attack the tumour. The study includes 56 adults with advanced solid tumours that have not responded to sta…

This study is for people with aggressive B-cell lymphoma that has come back or not responded to treatment. Researchers are testing a new drug combined with standard chemotherapy to find the highest safe dose. The goal is to control the disease and improve outcomes, not to cure it…

This study compares two types of brachytherapy (radiation placed directly into the prostate) for men with localized prostate cancer. One type uses a high dose of radiation given in two sessions, the other uses low-dose radioactive seeds left in place. The goal is to see how well …

This study tests whether using the immunotherapy drug durvalumab (with or without another drug, tremelimumab) alongside radiation is better than the standard treatment of chemotherapy (cisplatin) plus radiation for patients with HPV-positive advanced throat cancer. The goal is to…

This study tests whether adding the drug durvalumab to standard treatment (surgery, chemotherapy, and radiation) helps prevent bladder cancer from coming back. About 82 adults with muscle-invasive bladder cancer that hasn't spread will take part. The goal is to see if the combina…

This study tests a drug called palbociclib in 19 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if it can shrink tumors or lower PSA levels, and to check for side effects. Researchers also look for markers to predict who might ben…

This study tested two drugs, sunitinib and temsirolimus, in 137 people with advanced rare cancers that cannot be cured. The goal was to see if these drugs could shrink tumors or slow cancer growth. While not a cure, the treatment aims to control the disease and improve outcomes f…

This study tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with or without chemotherapy can help people with stage IV non-small cell lung cancer live longer. The drugs help the immune system recognize and attack cancer cells. The trial enrolled 301 p…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together with standard chemotherapy, in people with advanced solid tumors that cannot be cured. The main goal is to find the safest dose that does not cause severe side effects. About 153 adults with …

This study tests a new drug called CFI-402257 combined with the standard chemotherapy paclitaxel in people with advanced HER2-negative breast cancer that cannot be cured. The goal is to see if the combination works better than paclitaxel alone at slowing tumor growth. About 37 wo…

This study tests whether adding a new drug called ipatasertib to standard hormone therapy (fulvestrant) can slow the growth of advanced breast cancer that has stopped responding to initial treatments. About 250 postmenopausal women with ER-positive, HER2-negative breast cancer wi…

This study tests whether taking aspirin can prevent ovarian cancer in women with BRCA1 or BRCA2 gene mutations, who are at high risk. About 117 participants will take either aspirin or a placebo daily for up to 2 years before their scheduled risk-reducing surgery. Researchers wil…

This study tests whether doctors can safely skip radiation to some lymph node areas in patients with low-risk HPV-related throat cancer. The goal is to reduce side effects without increasing the chance of the cancer coming back. About 103 patients are taking part, and researchers…

This study looked at the costs and quality-of-life benefits of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared a standard chemo-immunotherapy combination (bendamustine plus rituximab) with two newer ibrutinib-based regim…